文献速递白血病

阿西米尼单药治疗BCR::ABL1 T315I突变慢性期CML的1期试验最终结果

Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.
PubMed 文献 · Leukemia · 2026-07-16

该1期非随机试验纳入48例BCR::ABL1 T315I突变慢性期CML患者,接受阿西米尼200 mg每日两次治疗,中位暴露3.5年。45例可评估患者中24例(53.3%)达到主要分子学反应(MMR),首次MMR维持至少144周的Kaplan-Meier估计比例为86%(95% CI: 71.9-100.0%)。安全性特征未显示新的或恶化的信号,≥3级不良事件发生率为60.4%,4例(8.3%)因不良事件停药。

要点

  • 阿西米尼200 mg每日两次在T315I突变CML-CP中诱导53.3%的MMR率。
  • 首次MMR维持至少144周的估计比例为86%(95% CI: 71.9-100.0%)。
  • 中位暴露3.5年,安全性无新信号,≥3级不良事件发生率60.4%。

核心结论

  • 阿西米尼单药对T315I突变CML-CP患者具有持久疗效和可接受的安全性。

研究设计与样本

  • 1期非随机试验(NCT02081378),纳入48例T315I突变CML-CP患者,接受阿西米尼200 mg每日两次。

主要发现

  • 中位暴露3.5年,52.1%的患者继续通过试验后途径接受阿西米尼。
  • 45例可评估患者中24例(53.3%)达到MMR,其中20例维持或加深反应。
  • 首次MMR维持至少144周的Kaplan-Meier估计比例为86%(95% CI: 71.9-100.0%)。
  • ≥3级不良事件发生率为60.4%,4例(8.3%)因不良事件停药。
  • 首次全等级AOEs的暴露调整发生率率为4.4例/100患者年。

临床怎么用

  • 对于T315I突变CML-CP患者,阿西米尼200 mg每日两次可作为治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In chronic myeloid leukemia in chronic phase (CML-CP), BCR::ABL1T315I commonly leads to treatment resistance, worse patient outcomes, and limited subsequent treatment options. By targeting the ABL1 myristoyl pocket, asciminib maintains activity against BCR::ABL1T315I. We report final long-term safety, tolerability, and efficacy results with asciminib in 48 patients with T315I-mutated CML-CP who received asciminib 200 mg twice daily in the phase 1, nonrandomized trial (NCT02081378). After a median exposure of 3.5 years, 52.1% of patients continued to receive asciminib via posttrial access. Of 45 evaluable patients, 24 (53.3%) achieved major molecular response (MMR); 20 of 24 maintained or deepened their response by the cutoff. The Kaplan-Meier estimated proportion of patients maintaining their first MMR for at least 144 weeks (2.8 years) was 86% (95% CI: 71.9-100.0%). The safety profile showed no new or worsening safety signals. With 1.4 years' additional exposure since the previous analysis, the incidence of grade ≥3 adverse events (AEs) (60.4%) did not increase. Four patients (8.3%) discontinued due to AEs. The exposure-adjusted incidence rate of first all-grade AOEs was 4.4 cases per 100 patient-years. With up to approximately 6 years of exposure, this final analysis confirms asciminib as a treatment option for patients with T315I-mutated CML-CP.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Cortes JE, Rea D, Mauro MJ, et al. Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results. Leukemia. 2026. PMID: 42463944. doi:10.1038/s41375-026-02972-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。